Neoantigen Dendritic Cell Vaccination Combined with Anti-CD38 and CpG Elicits Anti-Tumor Immunity against the Immune Checkpoint Therapy-Resistant Murine Lung Cancer Cell Line LLC1
/in Dendritic Cells, International Publications, NSCLC /von 2021-11-02 / Cancers (Basel) 2021 Nov;13(21)Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End
/in Dendritic Cells, Glioblastoma, International Publications /von 2021-11-02 / Front Immunol 2021;12:770390The Efficacy of Dendritic Cell Vaccine for Newly Diagnosed Glioblastoma: A Meta-analysis of Randomized Controlled Studies
/in Dendritic Cells, Glioblastoma, International Publications /von 2021-11-01 / Clin Neuropharmacol 2021 Nov-Dec 01;44(6):216-221Recent Advances in Experimental Dendritic Cell Vaccines for Cancer
/in Dendritic Cells, International Publications /von 2021-09-23 / Front Oncol 2021;11:730824Targeting CD166 lung cancer stem cells: Molecular study using murine dendritic cell vaccine
/in Dendritic Cells, International Publications, NSCLC, SCLC /von 2021-08-23 / Toxicol Appl Pharmacol 2021 Oct;429:115699Long-term follow up of patients with mesothelioma treated with dendritic cell therapy in three phase I trials.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2021-08-09 / J Clin Oncol 39, 2021 (suppl 15; abstr 2618)Phase 1 trial of autologous dendritic cell vaccination with imiquimod immunomodulation in children and adults with refractory sarcoma.
/in Dendritic Cells, International Publications, Soft Tissue Sarcoma /von 2021-08-09 / J Clin Oncol 39, 2021 (suppl 15; abstr 11542)Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2021-08-01 / Melanoma Res 2021 Aug;31(4):378-388Prognostic Factors for Advanced/Recurrent Breast Cancer Treated With Immune-cell Therapy
/in Breast Cancer, Dendritic Cells, International Publications /von 2021-08-01 / Anticancer Res 2021 Aug;41(8):4133-4141IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de